jueves, 26 de abril de 2018

Unusual Antibiotic resistance: Early, Aggressive Action Can Prevent Spre...



Containing Unusual Resistance | VitalSigns | CDC

Interim Guidance for a Health Response to Contain Novel or Targeted Multidrug-resistant Organisms (MDROs)

Guidelines | Containment | HAI | CDC
Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People

Interim Guidance for a Health Response to Contain Novel or Targeted Multidrug-resistant Organisms (MDROs)

Cover to Interim guidance for a Public health response to contain novel and targeted MDRO's
This document is intended for state and local health departments and healthcare facilities and serves as general guidance for the initial response for the containment of novel or targeted multidrug-resistant organisms (MDROs) or resistance mechanisms.

Laboratorians protect patients from antibiotic resistance

Lab Experts Sound the Alarm to Protect Us
from Antibiotic Resistance
It’s Medical Laboratory Professionals Week, April 22-28.
Vital Signs Factoid

Working behind the scenes, lab professionals provide the testing to help figure out what is making people sick and determine what treatment will help them get better. Laboratorians also play a key role in finding “unusual” antibiotic resistance (AR) early, before it becomes common, so that response teams can quickly investigate to stop spread and protect people from difficult-to-treat infections.
The most recent CDC Vital Signs report highlights the importance of rapid detection by laboratorians, the critical first step in the Containment Strategy. The report also includes data fromCDC’s AR Lab Network, a new resource that can help identify and characterize resistance in threats like “nightmare bacteria” carbapenem-resistant Enterobacteriaceae (CRE), emerging fungal threats like Candida auris, and even food and community pathogens. Using the AR Lab Network, nationwide testing uncovered unusual resistance genes in “nightmare bacteria” more than 220 times in 2017.
Thank you to the many laboratory professionals who serve the public every day. Your work on the frontlines is critical in the fight against antibiotic resistance!   

A Seat at the Table: Culturally based cancer research among American Ind...



04/26/2018 09:36 AM EDT
 

NCI supports research to address cancer disparities among American Indian and Alaska Native populations. In this video, two researchers advocate for more culturally sensitive practices to help people who are most disproportionately affected by cancer disparities. Audio Described version: youtu.be/RkvOwnx4xVo

Drug for a rare genetic disorder works in kids treated in mothers' womb

Drug for a rare genetic disorder works in kids treated in mothers' womb

STAT

‘A full rescue’: Drug injected before birth treats rare genetic disorder



As soon as she saw her baby, Sarah Yaroch knew. Her father had the disorder, as did her nephew, and now she could see the telltale signs in her own newborn son Andrew. He had no eyebrows, no hair, and skin that seemed too pale and thin. A genetic mutation had deprived him of a specific protein as he developed in the womb, and without it, his body could not properly form sweat glands and teeth and other organs.
Within two weeks, though, he was brought from Waterford, Mich., to St. Louis, where doctors infused an experimental lab-grown version of the protein into his tiny veins. The hope was that giving this molecule just after birth might compensate for what had been missing during pregnancy.

The U.S. Department of Health and Human Services and the American Society of Nephrology to Launch Kidney Innovation Accelerator

KidneyX | Innovation Accelerator

The U.S. Department of Health and Human Services and the American Society of Nephrology to Launch Kidney Innovation Accelerator


The U.S. Department of Health and Human Services (HHS) is pleased to announce a partnership with the American Society of Nephrology to launch the Kidney Innovation Accelerator (KidneyX), KidneyX will engage a community of researchers, innovators, and investors to enable and accelerate the commercialization of therapies to benefit people with and at risk for kidney diseases through a series of prize competitions and coordination among federal agencies and the private sector.
More than 40 million Americans live with kidney diseases and 703,243 experience kidney failure. With an aging population and rising prevalence of diabetes and hypertension, more Americans need dialysis than ever before. Patients with chronic kidney disease continue to have limited treatment options and are particularly vulnerable in natural disasters when local dialysis centers are damaged or closed for more than a few days.
“Over the last decade, patients with cancer and heart disease have benefitted from innovative improvements in therapies, drugs, devices and digital health tools. Patients suffering from kidney disease deserve the same opportunity. With KidneyX, HHS sends an important message to innovators and investors regarding the desire and demand to help patients suffering from chronic kidney disease,” said HHS Chief Technology Officer, Bruce D. Greenstein.
To prevent kidney diseases as well as improve the lives of the 850,000,000 people worldwide currently affected, KidneyX will accelerate innovation in the prevention, diagnosis, and treatment of kidney diseases. KidneyX will address the barriers innovators commonly identify as they look to bring new drugs and technologies in kidney care to market by:
  • Providing funding through prizes to promising innovators selected through a prize competition;
  • Encouraging better coordination across the HHS agencies including the National Institutes of Health, the Food and Drug Administration, and the Centers for Medicare & Medicaid Services in order to help clarify the path toward commercialization;
  • Creating a sense of urgency to develop new therapies to treat chronic kidney disease
“By launching KidneyX, ASN and HHS have sent a clear signal that the kidney space is ripe for accelerating innovation in the fight against kidney diseases. KidneyX will serve as that catalyst while encouraging the venture capital community that has previously been reluctant to invest in kidney therapeutics to revisit it as a target for potential investments,” said ASN President, Mark D. Okusa, MD, FASN.
KidneyX will accept applications for its first round of prize funding in late summer 2018. Individuals who are interested in learning more about KidneyX are encouraged to visit www.kidneyx.org and join the mailing list.

Metformin and Vitamin B12 Deficiency | NIDDK

Metformin and Vitamin B12 Deficiency | NIDDK

Blog Post Banner

04/25/2018 12:00 AM EDT


Providers need to be aware of the possibility of B12 deficiency and monitor patients.